Contributions
Abstract: P534
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Backgrounds: The spasticity syndrome is a significant factor in the development of disability. However pathogenesis of spasticity is complex and not not fully understood.
Introduction. Our aim was to assess neuromediators level in motor cortex during effective treatment of spasticity in patients with secondary-progressive multiple sclerosis (SPMS).
Methods: Thirty four patients (14 males, mean age 47±11) with SPMS and lower spastic paraparesis were enrolled in double-blind placebo-control study. To explore neuromediators level we used single voxel proton magnetic resonance spectroscopy (H-MRS). Voxel was placed in the senso-motorial region. Patients were divided into 3 groups: two of them received real repetitive transcranial magnetic stimulation (rTMS) (20 Hz or iTBS) of motor cortex and one - sham stimulation. For assessment spasticity level we used Modified Ashworth Scale (MAS), Subjective Evaluation Spasticity Scale (SESS) before and at the end of 10 rTMS sessions, SESS 2 weeks and 12 weeks after of 10 rTMS sessions.
Results: In contrast with sham group, in both treatment groups were statistically significant reduction of spasticity level on MAS and SESS. But in iTBS group the effect was stronger and persisted for 12 weeks, instead of 2 weeks in 20 Hz group. With this correlation we noticed significant increase N-acetilaspartat/creatin level only in iTBS group after treatment. This findings could indicate the relationship between the level of spasticity and neuromediators level in senso-motorial region of motor cortex.
Conclusions: Our results indicate that spasticity associated with neuromediators level. Future trials will provide us more evident information.
Disclosure: Nothing to disclose.
Abstract: P534
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Backgrounds: The spasticity syndrome is a significant factor in the development of disability. However pathogenesis of spasticity is complex and not not fully understood.
Introduction. Our aim was to assess neuromediators level in motor cortex during effective treatment of spasticity in patients with secondary-progressive multiple sclerosis (SPMS).
Methods: Thirty four patients (14 males, mean age 47±11) with SPMS and lower spastic paraparesis were enrolled in double-blind placebo-control study. To explore neuromediators level we used single voxel proton magnetic resonance spectroscopy (H-MRS). Voxel was placed in the senso-motorial region. Patients were divided into 3 groups: two of them received real repetitive transcranial magnetic stimulation (rTMS) (20 Hz or iTBS) of motor cortex and one - sham stimulation. For assessment spasticity level we used Modified Ashworth Scale (MAS), Subjective Evaluation Spasticity Scale (SESS) before and at the end of 10 rTMS sessions, SESS 2 weeks and 12 weeks after of 10 rTMS sessions.
Results: In contrast with sham group, in both treatment groups were statistically significant reduction of spasticity level on MAS and SESS. But in iTBS group the effect was stronger and persisted for 12 weeks, instead of 2 weeks in 20 Hz group. With this correlation we noticed significant increase N-acetilaspartat/creatin level only in iTBS group after treatment. This findings could indicate the relationship between the level of spasticity and neuromediators level in senso-motorial region of motor cortex.
Conclusions: Our results indicate that spasticity associated with neuromediators level. Future trials will provide us more evident information.
Disclosure: Nothing to disclose.